US009409939B2

(12) **United States Patent**
Wang et al.

(10) **Patent No.: US 9,409,939 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **QUANTIFICATION METHOD FOR REMAINING LIVER FUNCTION AND NOVEL LIVER RECEPTOR IMAGING AGENT**

(71) Applicant: **INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN**, Taoyuan County (TW)

(72) Inventors: **Mei-Hui Wang**, Taoyuan County (TW); **Wuu-Jyh Lin**, Taoyuan County (TW); **Chuan-Yi Chien**, Taoyuan County (TW); **Hung-Man Yu**, Taoyuan County (TW); **Reiko Takasaka Lee**, Baltimore, MD (US); **Yuan-Chuan Lee**, Baltimore, MD (US)

(73) Assignee: **INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN**, Taoyuan (TW)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 155 days.

(21) Appl. No.: **13/858,213**

(22) Filed: **Apr. 8, 2013**

(65) **Prior Publication Data**

US 2013/0225798 A1 Aug. 29, 2013

Related U.S. Application Data

(62) Division of application No. 12/779,374, filed on May 13, 2010, now Pat. No. 8,435,491.

(30) **Foreign Application Priority Data**

Oct. 26, 2009 (TW) ..... 98136146 A

(51) **Int. Cl.**

A61K 51/00	(2006.01)
A61M 36/14	(2006.01)
C07H 15/04	(2006.01)
A61K 51/04	(2006.01)

(52) **U.S. Cl.**

CPC ***C07H 15/04*** (2013.01); ***A61K 51/0491*** (2013.01); ***A61K 51/0497*** (2013.01)

(58) **Field of Classification Search**

CPC A61K 51/00; A61K 51/08; A61K 51/088; A61K 51/04; A61K 51/0491; A61K 51/0497; C07H 15/04

USPC 424/1.11, 1.65, 1.69, 1.73, 9.1, 9.6; 534/7, 10–16; 514/1, 1.1

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,010,251	A *	3/1977	Green	424/1.49
6,350,431	B1 *	2/2002	Snow	A61K 41/0033 424/9.6
8,142,759	B2 *	3/2012	Wang et al.	424/1.69
8,435,491	B2 *	5/2013	Wang et al.	424/1.69
8,552,163	B2 *	10/2013	Lee et al.	536/17.9
8,961,931	B2 *	2/2015	Duh et al.	424/1.89
9,040,017	B2 *	5/2015	Wang et al.	424/1.11

OTHER PUBLICATIONS

Lee et al, Bioorganic & Medicinal Chemistry, 2011, vol. 19, pp. 2494-2500.*

Ljungberg, et al., "3D Absorbed Dose Calculations Based on SPECT: Evaluation for 111-In/90-Y Therapy using Monte Carlo Simulations. ", 2003, pp. 99-107, vol. 18, No. 1, Cancer Biotherapy & Radiopharmaceuticals.

Royal, et al., "Society of Nuclear Medicine Procedure Guideline for Hepatic and Splenic Imaging 3.0", Jul. 20, 2003, pp. 53-57, Society of Nuclear Medicine Procedure Guidelines Manual.

Kwon, et al., "Functional Hepatic Volume Measured by Technetium-99m-Galactosyl-Human Serum Albumin Liver Scintigraphy: Comparison Between Hepatocyte Volume and Liver Volume by Computed Tomography", 2001, pp. 541-546, vol. 96, No. 2, The American Journal of Gastroenterology.

Miederer, et al., "Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications", 2008, pp. 1371-1382, Advanced Drug Delivery Reviews.

Virgolini, et al., "Decreased hepatic function in patients with hepatoma or liver metastasis monitored by a hepatocyte specific galactosylated radioligand.", 1990, pp. 937-941, Macmillan Press Ltd.

Korf, et al., "Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in mice", Jun. 2009, pp. 1826-1837, vol. 119, No. 6, The Journal of Clinical Investigation.

Mahley, et al., "Two Independent Lipoprotein Receptors on Hepatic Membranes of Dog, Swine, and Man", Nov. 1981, pp. 1197-1206, vol. 68, The American Society for Clinical Investigation, Inc.

Yu, et al., "Radiolabeling and MicroSPECT/CT Imaging of a Novel Multivalent Glycopeptide for Asialoglycoprotein Receptor Imaging", Sep. 2009, vol. 22, Annals of Nuclear Medicine and Sciences.

Satoh, et al., "99mTc-GSA liver dynamic SPECT for the preoperative assessment of hepatectomy", 2003, pp. 61-67, vol. 17, No. 1, Annals of Nuclear Medicine.

* cited by examiner

Primary Examiner — D L Jones

(74) *Attorney, Agent, or Firm* — WPAT, PC; Justin King

(57) **ABSTRACT**

A test indicator for quantifying remaining liver function is provided. A novel liver receptor imaging agent with liver targeting property is utilized to develop a method for quantifying remaining liver function to serve as test indicator for judging the liver failure outcome in clinic, particularly for judging the necessity of liver transplantation for patients with liver failure or liver disease. The radioactivity uptake of the test indicator was negatively correlated with the extent of liver reserve. The cutoff value of liver reserve for liver transplantation is also disclosed.

1 Claim, 9 Drawing Sheets